ExaGrid Named “Recommended” Solution for Deduplication Backup Target Appliances by DCIG
ExaGrid ®, a leading provider of hyper-converged secondary storage (HCSS) for backup with data deduplication, today announced that independent analyst firm DCIG once again ranked the ExaGrid disk-based backup appliance in the top category of “Recommended” in its recently published 2018 Deduplication Backup Target Appliance Buyer’s Guide. This body of research assists organizations in matching their business and technical requirements for disk-based backup to best available products.
“This is the fourth consecutive year that ExaGrid has earned top-most positions in the DCIG Buyer’s Guides, which continues to validate the power of our differentiated product architecture and the speed and reliability it delivers,” said Bill Andrews, CEO of ExaGrid. “We’re very proud of this continued distinction.”
DCIG’s analysts concluded that ExaGrid’s unique architecture that combines a landing zone and full appliances in a single scale-out system differentiates its solution from those of its competitors. According to Jerome Wendt, President & Lead Analyst at DCIG, “Enterprises need faster, more scalable, easier to manage deduplication backup target appliances that also accelerate recoveries than ever before. The ExaGrid EX40000E and EX32000, ranked as ‘Recommended’ in the DCIG 2018 Deduplication Backup Target Appliance Buyer’s Guide, exemplify these requirements. ExaGrid’s solutions provide enterprises with the features they need to meet and exceed their backup and recovery requirements while delivering the scalability and simplicity they expect.”
According to the report, ExaGrid’s scale-out architecture, unique landing zone, ongoing virtualization enhancements, and seamless deployments helped the EX40000E and EX32000E appliances place in the top category of “Recommended.” ExaGrid, with its scale-out backup storage and unique landing zone, is 3 times faster for ingest and over 20 times faster for restores and VM boots than its closest competitor. In addition, ExaGrid is the only solution that provides a fixed-length backup window as data grows. With ExaGrid, IT can have the fastest backups, restores, and VM boots; a fixed-length backup window; and the ability to easily scale their systems, so they simply buy what they need as they need it, all at the lowest cost up front and over time. ExaGrid eliminates forklift upgrades and product obsolescence.
The DCIG 2018 Deduplication Backup Target Appliance Buyer’s Guide drives time and cost out of the product selection process by enabling prospective buyers to more quickly identify a shortlist of products that meet their specific needs. Thus, prospective purchasers can focus their product evaluation energies and move more quickly to buying the best solution for them.
DCIG is a group of analysts with IT industry expertise who provide informed, insightful, third party analysis and commentary on IT hardware, software and services. DCIG independently develops and licenses access to DCIG Buyer's Guide Editions. DCIG Buyer's Guides provide actionable intelligence through comprehensive, in-depth analysis of data center infrastructure product features. DCIG also develops sponsored content in the form of blog entries, customer validations, product reviews, special reports and executive, standard and full-length white papers. DCIG's target audiences include C-level executives, IT managers, systems and storage engineers and architects, press/media, magazine and website editors, bloggers, financial and technical analysts, and cloud service providers. More information is available at http://www.dcig.com .
ExaGrid provides hyper-converged secondary storage for backup with data deduplication, a unique landing zone, and scale-out architecture. ExaGrid’s landing zone provides for the fastest backups, restores, and instant VM recoveries. Its scale-out architecture includes full appliances in a scale-out system and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades. Follow us @ExaGrid and LinkedIn, and visit exagrid.com. See what ExaGrid customers have to say about their own ExaGrid experiences and why they now spend significantly less time on backup.
ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.
Christine Murphy, 508-898-2872 x248
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 10:45 | Pressemelding
Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial
Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 09:10 | Pressemelding
Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30 | Pressemelding
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent
Manchester United and True Religion Launch Denim Range19.10.2018 17:37 | Pressemelding
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10 | Pressemelding
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an